Rein Therapeutics
RNTX
64 hedge funds and large institutions have $33.1M invested in Rein Therapeutics in 2026 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
10% more capital inflows, than outflows
Capital inflows: $1.81M | Capital outflows: $1.64M
7% more funds holding
Funds holding: 60 → 64 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 47.75% → 47.68% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voss Capital
Houston,
Texas
|
+$482K |
| 2 |
Prosight Management
Dallas,
Texas
|
+$459K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$130K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$91.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Great Point Partners
Greenwich,
Connecticut
|
-$748K |
| 2 |
Empery Asset Management
New York
|
-$386K |
| 3 |
Stonepine Capital Management
Bend,
Oregon
|
-$227K |
| 4 |
Corsair Capital Management
New York
|
-$83.2K |
| 5 |
Goldman Sachs
New York
|
-$83K |
RNTX Hedge Fund Activity: Q3 2026 in Review
64 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2026, worth a combined $33.1M — down 22% from $42.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RNTX positions and 6 closed out — a net gain of 5 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Voss Capital, adding an estimated $482K. The largest seller was Great Point Partners, cutting an estimated $748K.
- 64 institutional investors held Rein Therapeutics (RNTX) as of Q3 2026, up from 60 in Q2 2026.
- Funds reported $33.1M of Rein Therapeutics stock for Q3 2026, down 22% quarter-over-quarter.
- 11 funds opened new Rein Therapeutics positions in Q3 2026 and 6 closed out, a net change of +5 holders.
- The largest Rein Therapeutics buyer in Q3 2026 was Voss Capital, an estimated $482K added.
- The largest Rein Therapeutics seller in Q3 2026 was Great Point Partners, an estimated $748K sold.
Based on aggregated 13F filings for Q3 2026.